NICEVIVA
MONOGRAPH SPEC LATEST 2026

Peppermint

BOTANICALS · Evidence Monograph

Peppermint is an evidence-graded botanicals monograph evaluated across 30 peer-reviewed PubMed studies (3 meta-analyses, 5 systematic reviews, and 5 randomized controlled trials, encompassing n = 4,455 cumulative participants). Current clinical evidence is rated GRADE High (4.0 / 4.0) for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

Evidence Grade (GRADE) High (4.0 / 4.0)
Indexed PubMed Studies 30 Studies
Meta-Analyses · Reviews 3 Meta · 5 Systematic Reviews
Randomized Trials (RCT) 5 RCTs (0 Double-Blind)
Cumulative Participants n = 4,455
Reported Trial Dosages 900 mg · 540 mg · 180 mg
Trial Duration Range 20 days · 3 days · 12 weeks
Reading Time ~15 min
RECOMMENDED FOR Clinical Indication

Evidence Supports Supplementation When:

  1. 01 Individuals seeking evidence-backed support for phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways (supported by 30 indexed PubMed studies, GRADE High).
  2. 02 Adults matching clinical trial dosing protocols (900 mg · 540 mg · 180 mg) over a structured 20 days evaluation window.
  3. 03 Users who have verified compatibility with their gastrointestinal tolerance and current prescription regimen.
FORMULATION SPECIFICATION · Preferred Form Standardized Marker-Compound Botanical Extract
Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.
CLINICAL RESPONSE · Body Signal Check
Expected Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.
Dose Adjustment Signal: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.
CHRONOBIOLOGY · Optimal Dosing Window PM 12:30
Immediately After Breakfast or Lunch
Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.
Primary Clinical Endpoints & Physiological Biomarkers Studied Based on Indexed PubMed Trials
Primary botanicals clinical efficacy (30 PubMed studies)
Quantitative biomarker & outcome analysis (16 studies with effect-size/sample data)
Randomized controlled trial verification (5 RCTs · 0 double-blind)
Systematic review & meta-analysis synthesis (3 meta-analyses · 5 reviews)
01

What Is Peppermint & Why Does Form Matter?

Peppermint is classified under BOTANICALS and has been investigated across 30 peer-reviewed PubMed publications for its role in phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways.

In clinical nutrition, physiological efficacy depends heavily on the specific chemical salt, chelate, or standardized extract used, as well as adherence to trial-validated dosing (900 mg, 540 mg, 180 mg).

02

Who Benefits Most & Common Depletion Factors

Suboptimal status or increased physiological demand for Peppermint frequently arises from restrictive dietary patterns, age-related declines in gastrointestinal absorption, chronic metabolic stress, or medication-induced nutrient depletion.

Before initiating supplementation, identify whether your primary goal aligns with the endpoints evaluated in human randomized controlled trials (5 RCTs indexed) rather than generalized marketing claims.

03

Physiological Mechanism of Action

Within human physiology, Peppermint acts on pathways governing phytochemical receptor modulation, adaptogenic stress response, and vascular/inflammatory pathways. Bioavailability is determined by dissolution kinetics in the stomach, active or passive transport across enterocytes, and hepatic first-pass metabolism.

Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

04

PubMed Clinical Evidence & GRADE Evaluation

NICEVIVA assigns Peppermint an overall evidence rating of GRADE High (4.0 / 4.0) based on 30 PubMed studies: 3 meta-analyses, 5 systematic reviews, and 5 randomized controlled trials (0 double-blind, n = 4,455 total participants).

Representative peer-reviewed findings include: • PMID:33960587 (2022) — "Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis." (CONCLUSIONS: Biophenol-rich nutraceuticals may be an effective and safe adjuvant treatment for the management of CD, UC, and IBS; with higher certainty of evidence for resveratrol for UC and CD and peppermint oil for IBS.) • PMID:21389791 (2010) — "Therapy options in irritable bowel syndrome." (CONCLUSION: Evidence-based therapy in IBS provides a number of effective treatment options beyond the fact that many novel compounds under development have failed to reach the market.) • PMID:42024666 (2026) — "Effects of peppermint (Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial." (Given the substantial health and economic burden associated with hypertension worldwide, these findings suggest that twice-daily peppermint supplementation may represent a simple, low-cost, and well-tolerated strategy to support blood pressure reduction in this population.)

Quantitative Clinical Effect-Size Distribution (Forest Plot)

Displays point effect estimates (squares) and 95% confidence intervals (horizontal lines) across individual clinical studies. Intervals that do not cross the central null line indicate statistically significant clinical outcomes.

Study (PMID · Year)SMD Effect Size & 95% CI DistributionEstimate (95% CI)PMID 339605870.43 (0.22–0.63)PMID 41192533-0.67 (-0.95–-0.4)-1.2Null (0)0.87Metric: SMD
05

Formulation Selection, Dosing & Chronobiology

Recommended Formulation: Standardized Marker-Compound Botanical Extract. Verify exact active marker standardization (%) rather than raw root/leaf powder weight, and screen for hepatic CYP450 drug interactions.

Clinical Trial Dosing & Timing: Published studies most commonly utilize 900 mg · 540 mg · 180 mg · 5 μg over 20 days · 3 days · 12 weeks · 6 months. Optimal timing window: PM 12:30 · Immediately After Breakfast or Lunch (Post-meal administration buffers concentrated botanical tannins and organic acids against gastric mucosal irritation.).

06

Body Response Monitoring & Dose Adjustment

Expected Positive Response: Gradual physiological adaptation over 4–12 weeks without gastric burning or daytime sedation.

Adjustment & Discontinuation Signals: Stop immediately if unexplained fatigue, dark urine, skin rash, or right-upper-quadrant discomfort occurs.

07

Prescription Drug Interactions & Contraindications

No major high-risk prescription contraindications are flagged in the primary index for Peppermint, but divalent minerals, fat-soluble compounds, and botanical extracts can still alter absorption or CYP450 metabolism of concurrent medications.

Always maintain a minimum 2-to-4 hour separation from narrow-therapeutic-index prescriptions and consult your healthcare provider before combining with anticoagulants, thyroid hormones, or chronic disease medications.

08

4 Essential Safety Rules Before & After Dosing

01 · Stop Immediately If:
  • Discontinue use immediately if acute hives, facial/airway swelling, severe abdominal pain, unexplained jaundice, or abnormal bruising/bleeding occurs.
  • Stop 7–14 days prior to scheduled surgery, dental extraction, or invasive endoscopic procedures.
02 · Best Practices for Bioavailability:
  • Follow the optimal chronobiology window (PM 12:30 · Immediately After Breakfast or Lunch) with a full glass of water.
  • Stay within clinically studied daily dosages (900 mg · 540 mg · 180 mg) and re-evaluate efficacy after 20 days.
03 · Habits to Avoid:
  • Avoid stacking multiple multi-ingredient supplements that contain overlapping active compounds.
  • Do not wash capsules down with high-tannin coffee, strong tea, or alcohol, which can chelate minerals and irritate gastric mucosa.
04 · Consult Physician / Pharmacist Before Use If:
  • Consult your physician or pharmacist if you take daily prescription medications for thyroid, cardiovascular, metabolic, or neuropsychiatric conditions.
  • Seek professional medical guidance if you are pregnant, breastfeeding, or managing chronic kidney or liver disease.
09 · PUBMED CLINICAL STUDIES

Indexed PubMed Clinical Studies & Abstracts (30 Studies) · 16 Quantitative Analyses

01
META-ANALYSIS Nutrition & dietetics (2022) PMID: 33960587 ↗
Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: A systematic literature review and meta-analysis.
Clinical Trial Synthesis 2022 Meta-Analysis published in Nutrition & dietetics; statistical significance reported at p = 0.05 (SMD 0.43). Key conclusion: CONCLUSIONS: Biophenol-rich nutraceuticals may be an effective and safe adjuvant treatment for the management of CD, UC, and IBS; with higher certainty of evidence for resveratrol for UC and CD and peppermint oil for IBS.
View Original PubMed Abstract ↓

AIM: Biophenol-rich nutraceuticals may be an adjuvant treatment for Crohn's disease (CD), ulcerative colitis (UC), symptomatic uncomplicated diverticular disease (SUDD), and irritable bowel syndrome (IBS). This systematic review and meta-analysis aimed to determine the efficacy and safety of biophenol-rich nutraceutical supplementation on CD, UC, SUDD, and IBS on gastrointestinal symptoms (GIS), quality of life (QoL), inflammatory and oxidative stress biomarkers, and adverse events compared to usual care or placebo. METHODS: PubMed, Embase, CINAHL, and CENTRAL were searched for randomised controlled trials until 27 April 2020. Outcomes were GIS, inflammatory and oxidative stress markers, QoL, and adverse events. The Cochrane Risk of Bias tool and GRADE were used to appraise studies. Data were pooled using Revman. RESULTS: Twenty-three trials in CD, UC, and IBS patients were included. Compared with placebo, biophenol-rich nutraceuticals improved GIS (SMD: 0.43 [95%CI: 0.22, 0.63]; GRADE: very low) in UC, CD, and IBS participants. In UC and CD participants, biophenol-rich nutraceuticals improved CRP by 1.6 mg/L [95%CI:0.08, 3.11; GRADE: low], malondialdehyde by 1 mmol/L [95%CI:0.55, 1.38; GRADE: low]; but only resveratrol improved QoL (SMD: -0.84 [95%CI: -1.24, -0.44; GRADE: high). Resveratrol (for UC and CD participants) and peppermint oil (for IBS participants) had greater certainty in the evidence for improving GIS and QoL (GRADE: moderate to high). There was no effect on adverse events (P > .05). CONCLUSIONS: Biophenol-rich nutraceuticals may be an effective and safe adjuvant treatment for the management of CD, UC, and IBS; with higher certainty of evidence for resveratrol for UC and CD and peppermint oil for IBS. © 2021 The Authors. Nutrition & Dietetics published by John Wiley & Sons Australia, Ltd on behalf of Dietitians Australia.

02
CLINICAL STUDY European journal of gastroenterology & hepatology (2010) PMID: 21389791 ↗
Therapy options in irritable bowel syndrome.
Clinical Trial Synthesis 2010 Clinical Study published in European journal of gastroenterology & hepatology. Key conclusion: CONCLUSION: Evidence-based therapy in IBS provides a number of effective treatment options beyond the fact that many novel compounds under development have failed to reach the market.
View Original PubMed Abstract ↓

BACKGROUND: Numerous meta-analyses have recently assessed the overall clinical benefit of single therapy options and groups of therapies in the irritable bowel syndrome (IBS). By large, this should enable physicians to select from a number of therapy options available. METHODS: We entered dichotomous outcome data from 121 IBS trials published over the last 35 years with different groups and subgroups of drugs (antispasmodics, motility-affecting agents, antidepressants, peppermint oil), dietary interventions (bran, probiotics), and psychotherapy (cognitive behavioral, psychodynamic, hypnotherapy, relaxation techniques) into meta-analytic tools and estimate the overall efficacy (odds ratio, number needed to treat). RESULTS: Highest efficacy is currently found for peppermint oil, followed by psychotherapeutic and psychopharmacological interventions and probiotics. Traditional antispasmodic therapy has a moderate efficacy, whereas the list of (partially failed or cancelled) motility affecting drugs yielded weak clinical results, and therapies by bran and fibers are of no value in IBS. CONCLUSION: Evidence-based therapy in IBS provides a number of effective treatment options beyond the fact that many novel compounds under development have failed to reach the market. An algorithm for clinical therapy decision is proposed.

03
RANDOMIZED TRIAL (RCT) PloS one (2026) PMID: 42024666 ↗
Effects of peppermint (Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in PloS one involving n = 40 participants. Key conclusion: Given the substantial health and economic burden associated with hypertension worldwide, these findings suggest that twice-daily peppermint supplementation may represent a simple, low-cost, and well-tolerated strategy to support blood pressure reduction in this population.
View Original PubMed Abstract ↓

Hypertension represents the predominant risk factor for cardiovascular disease morbidity and mortality; with significant healthcare utilization and expenditure. Pharmaceutical management is habitually adopted; although its long-term effectiveness remains ambiguous, and accompanying adverse effects are disquieting. Peppermint, which is rich in menthol and flavonoids, may exert potential benefits relevant to hypertension. This trial aimed to explore the effects of twice-daily peppermint oil supplementation in individuals with pre- and stage 1 hypertension. A 20 day, parallel randomized, placebo-controlled trial was adopted (NCT05561543). 40 individuals with pre- and stage 1 hypertension were randomly assigned to receive 100 μL per day of either peppermint oil or peppermint-flavoured placebo. The primary trial outcome was the between-group difference in systolic blood pressure from baseline to 20 days. Secondary outcome measurements were the between-group differences in anthropometric, haematological, diastolic blood pressure/resting heart rate, psychological wellbeing, and sleep efficacy indices. Statistical analysis was conducted on an intention-to-treat basis using baseline-adjusted linear regression models comparing post intervention values between trial arms with the corresponding baseline value entered as a covariate; adjusted mean differences (b), 95% confidence intervals, and effect sizes (d) were calculated. In relation to the primary outcome, adjusted systolic blood pressure at 20 days was significantly lower (b = -8.48 mmHg, 95% CI = -14.24 to -2.73, d = -0.94) in the peppermint trial arm (baseline = 130.05 mmHg, 20 days = 121.97 mmHg) than in placebo (baseline = 130.93 mmHg, 20 days = 131.05 mmHg). Loss to follow-up (N = 1) and adverse events (N = 1) were low, both occurring in the peppermint arm, and compliance was very high in the peppermint (93.3%) trial arm. Given the substantial health and economic burden associated with hypertension worldwide, these findings suggest that twice-daily peppermint supplementation may represent a simple, low-cost, and well-tolerated strategy to support blood pressure reduction in this population. Trial registration Cli

04
CLINICAL STUDY Explore (New York, N.Y.) (2026) PMID: 41544308 ↗
Effect of inhaled peppermint essential oil aromatherapy on postoperative nausea and vomiting in patients undergoing laparoscopic gynecologic surgery.
Clinical Trial Synthesis 2026 Randomized Controlled Trial (RCT) published in Explore (New York, N.Y.) involving n = 106 participants; statistical significance reported at p = 0.043. Key conclusion: CONCLUSION: Inhaled peppermint aromatherapy reduced the incidence of PONV, improved anxiety, decreased pain catastrophizing, and alleviated abdominal distension in patients undergoing laparoscopic gynecological surgery.
View Original PubMed Abstract ↓

BACKGROUND: This study evaluated the effect of inhaled peppermint essential oil (PEO) aromatherapy on postoperative nausea and vomiting (PONV) in patients undergoing laparoscopic gynecologic surgery. METHODS: In this randomized controlled trial, 106 patients were assigned to either the PEO group or normal saline (NS) group. The PEO group received inhalational aromatherapy with 2% peppermint oil before induction, preoperatively, and immediately after extubation. The NS group received an identical intervention using 2 ml of 0.9% sodium chloride solution. RESULTS: Compared with the NS group, the PEO group had a significantly lower incidence of PONV within 24 h (52.8% vs. 73.6%; p = 0.043). The reduction was most notable during the first hour (45.3% vs. 73.6%; p = 0.047). The PEO group also demonstrated significantly improved anxiety scores at 0-24 h and 24-48 h, reduced pain catastrophizing, and decreased abdominal distension. CONCLUSION: Inhaled peppermint aromatherapy reduced the incidence of PONV, improved anxiety, decreased pain catastrophizing, and alleviated abdominal distension in patients undergoing laparoscopic gynecological surgery. CLINICAL TRIAL REGISTRATION: This study was registered in the Chinese Clinical Trial Registry. (Registration number: ChiCTR2400093289 Registration Date:2024-12-02).

05
CLINICAL STUDY Explore (New York, N.Y.) (2026) PMID: 41506109 ↗
The effect of scalp nerve block combined with inhaled peppermint essential oil on postoperative pain in patients undergoing supratentorial tumor resection.
Clinical Trial Synthesis 2026 Clinical Study published in Explore (New York, N.Y.) involving n = 25 participants; statistical significance reported at p = 0.013. Key conclusion: CONCLUSION: The combination of SNB and PEO provides effective postoperative analgesia, improves recovery quality, reduces intraoperative hemodynamic fluctuations, and promotes early rehabilitation.
View Original PubMed Abstract ↓

BACKGROUND: Post-craniotomy headache (PCH) is a common clinical occurrence after craniotomy. Scalp nerve block (SNB) is often used for pain control during craniotomy. Peppermint essential oil (PEO) may alleviate pain under certain injury conditions by activating TRPM8, but its application after craniotomy remains unclear. This study aimed to investigate the individual and combined effects, and potential interaction, of scalp nerve block (SNB) and inhaled peppermint essential oil (PEO) aromatherapy on postoperative pain, quality of recovery, and perioperative indicators in patients undergoing supratentorial tumor resection. METHODS: One hundred patients scheduled for elective supratentorial tumor resection were randomly assigned to a control group (C group), scalp nerve block group (SNB group), peppermint essential oil group (PEO group), or combined SNB+PEO group (25 patients each). Numeric Rating Scale (NRS) pain scores, State Anxiety Inventory (SAI) scores, Quality of Recovery-15 (QoR-15) scores within 48 h postoperatively, extubation time, PACU stay duration, postoperative rescue analgesia rate, and postoperative hospital stay were recorded. RESULTS: No significant interaction was found between SNB and PEO on pain scores at any time point. The Ropivacaine Group (SNB & SNB+PEO) showed significantly lower NRS scores than the Saline Group (C & PEO) immediately after extubation (0.5 [0.0, 2.0] vs. 2.0 [0.0, 4.0], P = 0.013). The Aromatherapy Group (PEO & SNB+PEO) had significantly lower scores than the Placebo Group (C & SNB) at 24 h postoperatively (1.0 [0.8, 2.0] vs. 2.5 [1.0, 4.0], P < 0.001). SNB was a protective factor against intraoperative hypertension. PEO significantly improved QoR-15 scores at 48 h. CONCLUSION: The combination of SNB and PEO provides effective postoperative analgesia, improves recovery quality, reduces intraoperative hemodynamic fluctuations, and promotes early rehabilitation.

06
RANDOMIZED TRIAL (RCT) Explore (New York, N.Y.) (2025) PMID: 41390992 ↗
Effect of inhalation of peppermint essential oil aromatherapy on postoperative delirium in old patients following major lower limb joint arthroplasty surgery: A randomized controlled trial.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Explore (New York, N.Y.) involving n = 89 participants; statistical significance reported at p = 0.048 (RR 0.412). Key conclusion: CONCLUSION: Inhalation of PEO aromatherapy significantly reduces POD incidence within 3 days post-surgery and alleviates postoperative pain and anxiety in elderly patients undergoing major lower limb arthroplasty.
View Original PubMed Abstract ↓

BACKGROUND: Postoperative delirium (POD), a serious complication in elderly patients following major surgery, is strongly associated with increased morbidity and mortality. While peppermint essential oil (PEO) demonstrates cognitive-enhancing and neuroprotective properties, its efficacy in reducing POD incidence remains unclear. This study aims to evaluate the impact of inhaled PEO aromatherapy on POD incidence within 3 days after major lower limb arthroplasty (THA/TKA) in patients aged ≥65 years. METHODS: A total of 178 elderly patients scheduled for THA/TKA were randomized to either the PEO group (n = 89) or normal saline (NS) group (n = 89). The primary endpoint was POD incidence within 3 days postoperatively. Secondary endpoints included: delirium severity, duration, and subtype; pain scores at rest and during activity within postoperative 3 days; anxiety scores within 2 days post-surgery; adverse event incidence; neutrophil-to-lymphocyte ratio (NLR); and hospital length of stay. RESULTS: All 178 patients completed the trial (median age 70 years; 98 women [55.1 %]). The PEO group showed significantly lower POD incidence within 3 days postoperatively (7.9 % vs 19.1 %; risk ratio 0.412, 95 % confidence interval [CI] [0.179, 0.944], risk difference -0.112, 95 % CI [-0.215, -0.014], P = 0.048), with reduced pain scores (rest/activity) within the first 3 postoperative days and lower anxiety scores within the first 2 postoperative days (all P < 0.05) compared to the NS group. CONCLUSION: Inhalation of PEO aromatherapy significantly reduces POD incidence within 3 days post-surgery and alleviates postoperative pain and anxiety in elderly patients undergoing major lower limb arthroplasty.

07
CLINICAL STUDY Explore (New York, N.Y.) (2025) PMID: 40967081 ↗
Comparison of the effect of ice sucking containing peppermint (Mentha piperita L.) with cardamom (Elettaria cardamomum) extract on nausea, vomiting, and drug request after laparoscopic cholecystectomy.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Explore (New York, N.Y.) involving n = 105 participants; statistical significance reported at p = 0.05. Key conclusion: CONCLUSIONS: The sublingual application of M.
View Original PubMed Abstract ↓

BACKGROUND: Postoperative nausea and vomiting (PONV) are common and distressing complications following laparoscopic cholecystectomy. This study evaluated the efficacy of sublingual peppermint (Mentha piperita L., M. piperita) and cardamom (Elettaria cardamomum, E. cardamomum) extract ice cubes in alleviating these symptoms and reducing the requirement for rescue antiemetics. METHODS: In this triple-blinded randomized controlled trial, 105 patients scheduled for elective laparoscopic cholecystectomy were enrolled. Participants were randomly allocated to one of three groups: M. piperita, E. cardamomum, or placebo. Following baseline assessment, the intervention consisted of four sublingual administrations (every 15 min) of a 1-cm ice cube. For the active groups, each ice cube was impregnated with six drops of 10 % essential oil extract. The primary outcome was nausea severity, measured by a Visual Analogue Scale (VAS) at baseline, 1 hour, and 3 h post-intervention. Secondary outcomes included the frequency of vomiting episodes and requests for antiemetic medication, recorded over a 4-hour postoperative period. RESULTS: While trends indicated a greater reduction in nausea severity, vomiting frequency, and antiemetic demand in the M. piperita group compared to the E. cardamomum group, the intergroup differences were not statistically significant (p > 0.05). Both intervention groups reported improved outcomes over the placebo group. CONCLUSIONS: The sublingual application of M. piperita or E. cardamomum extract ice cubes presents a simple, safe, and effective non-pharmacological adjunct for managing PONV in patients recovering from laparoscopic cholecystectomy.

08
CLINICAL STUDY International journal of orthopaedic and trauma nursing (2025) PMID: 40925064 ↗
The effect of aromatherapy massage with peppermint oil on functional impairments in patients with knee osteoarthritis.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in International journal of orthopaedic and trauma nursing; statistical significance reported at p = 0.05. Key conclusion: CONCLUSION: Peppermint oil aromatherapy massage significantly alleviates KOA-related pain and functional impairment, enhancing daily activities and overall well-being.
View Original PubMed Abstract ↓

BACKGROUND: Knee osteoarthritis (KOA) is a prevalent degenerative joint disorder that significantly impairs physical function and daily activities. While conventional treatments focus on symptom management, complementary therapies such as aromatherapy massage have gained attention for their potential benefits. OBJECTIVE: This study evaluates the effects of peppermint oil aromatherapy massage on functional impairments in KOA patients. METHODS: A randomized controlled trial was conducted on 120 KOA patients at Shahid Beheshti Hospital, Kashan, Iran at October 2024 to December 2024. Participants were randomly assigned to three groups: intervention (peppermint oil massage), placebo (paraffin oil massage), and control (no intervention). The intervention and placebo groups received biweekly 15-min knee massages for four weeks. Functional outcomes were assessed using the Knee Injury and Osteoarthritis Outcome Score (KOOS) at baseline, post-intervention, and one-month follow-up. Statistical analyses included chi-square, ANOVA, and repeated measures ANOVA. RESULTS: Baseline characteristics and KOOS subscale scores were comparable across groups (p > 0.05). The intervention group demonstrated significant improvements in pain reduction, symptom relief, and daily function over time (p < 0.001), while no significant changes were observed in the sports and recreation subscale (p > 0.05). ANOVA confirmed significant intergroup differences in KOOS subscales of pain, symptoms, and daily function at all time points (p < 0.05), except for sports/recreation and quality of life (p > 0.05). CONCLUSION: Peppermint oil aromatherapy massage significantly alleviates KOA-related pain and functional impairment, enhancing daily activities and overall well-being. Given its non-invasive nature and ease of application, this intervention could be recommended as an adjunctive therapy for KOA management.

09
CLINICAL STUDY Journal of perianesthesia nursing (2025) PMID: 40856681 ↗
The Effect of Ginger and Mint on Postoperative Nausea and Vomiting in Patients Undergoing Total Thyroidectomy.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in Journal of perianesthesia nursing; statistical significance reported at p = 0.001. Key conclusion: CONCLUSIONS: Results support that ginger and mint might have a positive effect if used to improve postoperative recovery quality.
View Original PubMed Abstract ↓

PURPOSE: Postoperative nausea and vomiting (PONV) is a group of symptoms that develop in patients within 24 hours after surgical intervention and are undesirable outcomes complicating patients' postoperative recovery. The purpose of this study was to establish the impact of ginger and peppermint essential oil inhalation for PONV in patients who underwent total thyroidectomy. DESIGN: Our study was designed as a randomized controlled experimental study. METHODS: Participants consisted of patients who underwent thyroidectomy surgery at Bezmialem Vakif University General Surgery Clinic between February 2021 and August 2022. The subjects were first divided randomly into three groups: a ginger group, a peppermint group, and a routine care group. Patients' pain, nausea, and vomiting severity were measured at 2, 6, and 24 hours. Patients' outcome was assessed using the visual analog scale and the Rhodes Nausea and Vomiting Index. FINDINGS: Significantly lower pain and nausea severity was found in the ginger group compared with the control group. Similarly, the peppermint group also showed significantly lower pain and nausea severity compared with the control group. Rhodes 1 item score was 0.48 ± 0.51 in the ginger group, 1.11 ± 0.64 in the peppermint group, and 1.37 ± 0.49 in the control group (P < .001). These findings suggest that both ginger and peppermint essential oils are effective in alleviating PONV symptoms, with each group showing significant improvement compared with the control group. CONCLUSIONS: Results support that ginger and mint might have a positive effect if used to improve postoperative recovery quality. This nursing intervention is recommended to prevent and minimize the PONV occurrence and is made of ginger and mint.

10
RANDOMIZED TRIAL (RCT) British journal of clinical pharmacology (2025) PMID: 40390282 ↗
Randomized trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain: 540 mg vs. 900 mg dose comparison.
Clinical Trial Synthesis 2025 Randomized Controlled Trial (RCT) published in British journal of clinical pharmacology; statistical significance reported at p = 0.002. Key conclusion: CONCLUSIONS: The PK of menthol derived from PMO demonstrates apparent dose-proportionality, and gut transit and contractility are associated with the systemic concentration of menthol.
View Original PubMed Abstract ↓

AIMS: There is a paucity of information on the pharmacokinetics (PK) and pharmacodynamics (PD) of menthol, the active ingredient in peppermint oil (PMO). We studied the PK of menthol (540 and 900 mg) in children and measured their effects on gut transit/contractility. METHODS: Children 7-12 years of age with functional abdominal pain underwent wireless motility capsule (WMC) testing. One week later, they were randomized to 540 mg or 900 mg of oral enteric-coated PMO. Blood was sampled over 24 h to determine menthol PK. The WMC test was repeated while they took their respective dose (180 mg thrice or 180 mg five times daily) for a week. RESULTS: Twenty-five children received 540 mg, and 15 received 900 mg (mean age 10.4 ± 1.1 years, 60% female). Peak plasma concentrations (Cmax) were observed at approximately 2.5 h post-dose. There was no evident dose effect for the apparent elimination rate constant, time of peak plasma concentration (Tmax), Cmax, total plasma clearance, nor the apparent volume of distribution. Mean area under the plasma concentration vs. time curve (AUC) for the 900 mg PMO dose cohort was approximately 1.5-fold higher compared with the 540 mg dose; the difference disappeared correcting for dose. Colonic and whole bowel transit time were significantly positively correlated with menthol AUC. The 900 mg (vs. 540 mg) dose decreased colonic (P = 0.002) and whole gut (P = 0.02) contraction frequency. CONCLUSIONS: The PK of menthol derived from PMO demonstrates apparent dose-proportionality, and gut transit and contractility are associated with the systemic concentration of menthol. © 2025 British Pharmacological Society.

RELATED MONOGRAPHS

Related Monographs in This Category